Chen Min, Li Wanqing, Zhang Xun, Dong Ye, Hua Yabing, Zhang Hui, Gao Jing, Zhao Liang, Li Ying, Zheng Aiping
State Key Laboratory of Toxicology and Medical Countermeasures, Beijing Institute of Pharmacology and Toxicology.
School of Pharmacy, Jinzhou Medical University, Jinzhou.
Int J Nanomedicine. 2017 Aug 1;12:5487-5500. doi: 10.2147/IJN.S133816. eCollection 2017.
7-Ethyl-10-hydroxycamptothecin (SN-38) is a potent broad-spectrum antitumor drug derived from irinotecan hydrochloride (CPT-11). Due to its poor solubility and instability of the active lactone ring, its clinical use is significantly limited. As one of the most promising formulations for poorly water-soluble drugs, nanocrystals have attracted increasing attention. In order to solve these problems and evaluate the antitumor effect of SN-38 in vitro and in vivo, two nanocrystals with markedly different particle sizes were prepared. Dynamic light scattering and transmission electron microscopy were used to investigate the two nanocrystals. The particle sizes of SN-38 nanocrystals A (SN-38/NCs-A) and SN-38 nanocrystals B (SN-38/NCs-B) were 229.5±1.99 and 799.2±14.44 nm, respectively. X-ray powder diffraction analysis showed that the crystalline state of SN-38 did not change in the size reduction process. An accelerated dissolution velocity of SN-38 was achieved by nanocrystals, and release rate of SN-38/NCs-A was significantly faster than that of SN-38/NCs-B. Cellular uptake, cellular cytotoxicity, pharmacokinetics, animal antitumor efficacy, and tissue distribution were subsequently examined. As a result, enhanced intracellular accumulation in HT1080 cells and cytotoxicity on different tumor cells were observed for SN-38/NCs-A compared to that for SN-38/NCs-B and solution. Besides, compared to the SN-38 solution, SN-38/NCs-A had a higher bioavailability after intravenous injection; while the bioavailability of SN-38/NCs-B was even lower than that of the SN-38 solution. SN-38/NCs-A exhibited a significant inhibition of tumor growth compared to SN-38 solution and SN-38/NCs-B in vivo. The antitumor effect of SN-38/NCs-B was stronger than SN-38 solution. The tissue distribution study in tumor-bearing mice showed that nanocrystals could markedly improve the drug accumulation in tumor tissue by the enhanced permeability and retention effect compared to SN-38 solution, and the amount of SN-38 in tumors of SN-38/NCs-A group was much more than that of SN-38/NCs-B group. In conclusion, nanocrystals dramatically enhanced the anticancer efficacy of SN-38 in vitro and in vivo, and the particle size had a significant influence on the dissolution behavior, pharmacokinetic properties, and tumor inhibition of nanocrystals.
7-乙基-10-羟基喜树碱(SN-38)是一种从盐酸伊立替康(CPT-11)衍生而来的强效广谱抗肿瘤药物。由于其溶解度差且活性内酯环不稳定,其临床应用受到显著限制。作为水溶性差的药物最有前景的制剂之一,纳米晶体已引起越来越多的关注。为了解决这些问题并评估SN-38在体外和体内的抗肿瘤作用,制备了两种粒径明显不同的纳米晶体。采用动态光散射和透射电子显微镜对这两种纳米晶体进行了研究。SN-38纳米晶体A(SN-38/NCs-A)和SN-38纳米晶体B(SN-38/NCs-B)的粒径分别为229.5±1.99和799.2±14.44 nm。X射线粉末衍射分析表明,SN-38的晶态在粒径减小过程中未发生变化。纳米晶体实现了SN-38加速溶解速度,且SN-38/NCs-A的释放速率明显快于SN-38/NCs-B。随后检测了细胞摄取、细胞毒性、药代动力学、动物抗肿瘤疗效和组织分布。结果显示,与SN-38/NCs-B和溶液相比,SN-38/NCs-A在HT1080细胞中的细胞内蓄积增强,对不同肿瘤细胞的细胞毒性增强。此外,与SN-38溶液相比,SN-38/NCs-A静脉注射后具有更高的生物利用度;而SN-38/NCs-B的生物利用度甚至低于SN-38溶液。与SN-38溶液和SN-38/NCs-B相比,SN-38/NCs-A在体内对肿瘤生长表现出显著抑制作用。SN-38/NCs-B的抗肿瘤作用强于SN-38溶液。对荷瘤小鼠的组织分布研究表明,与SN-38溶液相比,纳米晶体通过增强的渗透和滞留效应可显著提高药物在肿瘤组织中的蓄积,且SN-38/NCs-A组肿瘤中SN-38的含量远高于SN-38/NCs-B组。总之,纳米晶体显著增强了SN-38在体外和体内的抗癌疗效,粒径对纳米晶体的溶解行为、药代动力学性质和肿瘤抑制有显著影响。